• Explore /
  • Poster
  • / Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).

Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).

Abstract Poster

Authors

null

Alice Nono Djotsa

Center for Innovations in Quality Effectiveness and Safety, Houston, TX

Alice Nono Djotsa , David Winski , Theresa Hoang-Anh Nguyen , Sara Ahmed , John H Strickler , Daniel Jacob Becker , Vishal Vashistha , Michael J. Kelley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3602)

DOI

10.1200/JCO.2023.41.16_suppl.3602

Abstract #

3602

Poster Bd #

302

Abstract Disclosures

Similar Posters

First Author: Mo Yang

First Author: John Leonard Fox

First Author: Anthony Sireci

First Author: Anik Patel